StreetInsider.com News Articles

Form 4 Definium Therapeutics, For: Sep 02 Filed by: Barrow Robert

Fri, 11 Sep 2026 11:35:00 -0400

si-local-file:///var/storage/secattach/20260911/27051800.html

Definium to present Phase 3 DT120 trial data at Psych Congress 2026

Thu, 10 Sep 2026 07:00:19 -0400

Definium Therapeutics (Nasdaq: DFTX) announced it will present six poster presentations at Psych Congress, taking place September 15 through 19 in New Orleans, Louisiana.

The presentations will include topline Phase 3 results from the company's Emerge and Voyage trials of DT120 (lysergide), an orally disintegrating tablet, in both major depressive disorder (MDD) and generalized anxiety disorder (GAD). An invited oral presentation on the Emerge Phase 3 MDD study is scheduled for the "Latest Discoveries & Emerging Trends in MDD" session on September 17 from 9:00 AM to 10:00 AM CDT in Great Hall A.

Five additional poster presentations are scheduled for September

Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026

Thu, 10 Sep 2026 07:00:00 -0400

Emerge Phase 3 study podium poster to be featured in “Latest Discoveries & Emerging Trends in MDD” session

New epidemiological research on risks associated with anxiety and depression plus five posters across clinical program

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced six poster presentations at the Psych Congress taking place September 15 through 19 in New Orleans, LA.

“This year at Psych Congress, we will share clinical findings from our DT120 Orally

Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026

Thu, 10 Sep 2026 07:00:00 -0400

Emerge Phase 3 study podium poster to be featured in “Latest Discoveries & Emerging Trends in MDD” session

New epidemiological research on risks associated with anxiety and depression plus five posters across clinical program

“This year at Psych Congress, we will share clinical findings from our DT120 Orally

Stifel Reiterates Buy Rating on Definium Therapeutics Inc (DFTX)

Wed, 02 Sep 2026 08:50:16 -0400

Stifel analyst Paul Matteis reiterated a Buy rating and $60.00 price target on Definium Therapeutics Inc (NASDAQ: DFTX).

The analyst commented, "We sat down with CEO Rob Barrow to discuss the catalyst-rich summer for DFTX capped by their second ph3 GAD readout later this month, plus next steps as they think about regulatory filing and commercialization. With strong clinical efficacy demonstrated in all their late-stage studies to date, we're optimistic heading into the Panorama readout, where inclusion of a 50µg arm was really done to improve the rigor of the overall study (the idea is to address patient expectations and mitigate

Definium Therapeutics (DFTX) call put ratio 1 call to 1.9 puts as share price down 3.6%

Mon, 31 Aug 2026 15:13:37 -0400

Definium Therapeutics (NASDAQ: DFTX) 30-day option implied volatility is at 88; compared to its 52-week of 64 to 156. Call put ratio 1 call to 1.9 puts as share price down 3.6%.

Stifel Reiterates Buy Rating on Definium Therapeutics Inc (DFTX)

Mon, 31 Aug 2026 09:25:51 -0400

Stifel analyst Paul Matteis reiterated a Buy rating and $60.00 price target on Definium Therapeutics Inc (NASDAQ: DFTX).

The analyst commented, "We recently hosted a dinner with DFTX CEO Rob Barrow, CMO Dan Karlin and CFO Brandi Roberts to discuss all things DT120. Notable topics included: (1) further appreciation on the strength of the Voyage data in a GAD-specific population, which teases out the robust anxiolytic effect of DT120 as separate from its mood benefits, (2) confidence in the upcoming Panorama data in Sept, where the statistical analysis solely focuses on 100ug vs pbo; the low dose 50ug arm is there

Stifel on Definium Therapeutics (DFTX) Post Mgmt Dinner Meet: 'Confident Overall in Regulatory/Commercial Dynamics'

Mon, 31 Aug 2026 05:16:51 -0400

Stifel on Definium Therapeutics (NASDAQ: DFTX) Post Mgmt Dinner Meet: 'Confident Overall in Regulatory/Commercial Dynamics'.

The analyst comments "We recently hosted a dinner with DFTX CEO Rob Barrow, CMO Dan Karlin and CFO Brandi Roberts to discuss all things DT120. Notable topics included: (1) further appreciation on the strength of the Voyage data in a GAD-specific population, which teases out the robust anxiolytic effect of DT120 as separate from its mood benefits, (2) confidence in the upcoming Panorama data in Sept, where the statistical analysis solely focuses on 100ug vs pbo; the low dose 50ug arm is there to influence patient

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events